SCHEMBL2944006

SCHEMBL2944006

CC(C)(CNc1ccc(S(=O)(=O)NC(=O)c2ccc(-c3ccc(F)cc3)cc2)cc1[N+](=O)[O-])Sc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 18/20 0.72
BCL2 P10415 14/20 0.72
MCL1 Q07820 9/20 0.62
AURKA O14965 1/20 0.62
PLK1 P53350 1/20 0.62
DYRK1A Q13627 1/20 0.62
MARK2 Q7KZI7 1/20 0.62
AURKB Q96GD4 1/20 0.62
PLK3 Q9H4B4 1/20 0.62
BCL2L2 Q92843 1/20 0.57
BAD Q92934 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2950574 0.91 BCL2L1 (0.73) BCL2L1BCL2MCL1AURKAPLK1
SCHEMBL2943747 0.87 BCL2L1 (0.66) BCL2L1BCL2MCL1AURKAPLK1
SCHEMBL2944351 0.84 BCL2L1 (1.00) BCL2L1BCL2MCL1AURKAPLK1
SCHEMBL2948667 0.83 BCL2L1 (0.72) BCL2L1BCL2MCL1AURKAPLK1
SCHEMBL2951004 0.81 BCL2L1 (0.65) BCL2L1BCL2MCL1AURKAPLK1
SCHEMBL2943803 0.81 BCL2L1 (0.66) BCL2L1BCL2BCL2L2
SCHEMBL6982442 0.80 BCL2L1 (0.69) BCL2L1BCL2MCL1AURKAPLK1
SCHEMBL2941626 0.80 BCL2L1 (0.69) BCL2L1BCL2MCL1AURKAPLK1
SCHEMBL2951874 0.80 BCL2L1 (0.67) BCL2L1BCL2MCL1AURKAPLK1
SCHEMBL2949758 0.79 BCL2L1 (0.74) BCL2L1BCL2MCL1AURKAPLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 US disclosed
US-7504512-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-03-17 US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 EP disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 BCL2L1 5/4885BCL2 3/4885MCL1 14/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 BCL2L1 4/4885BCL2 3/4885MCL1 11/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 BCL2L1 5/4885BCL2 3/4885MCL1 14/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR BCL2L1 6/4885BCL2 2/4885MCL1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.